Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China

Korábbi kezelés

• Participants who received reserpine within 20 days of deutetrabenazine treatment initiation
• Participants who received monoamine oxidase inhibitors within 14 days of deutetrabenazine treatment initiation
• Participants who received vesicular monoamine transporter 2 (VMAT2) inhibitors, e.g., tetrabenazine or valbenazine, within 30 days of deutetrabenazine treatment initiation
• Participants who are participating in another study that includes treatment with an investigational drug and/or intervention at the same time as enrolment in the current study

Más betegség

• Participants who have an unstable or serious medical or psychiatric illness at baseline
• Participants with any history of suicidality, untreated or inadequately treated depression

Laborértékek

• Participants with certain comorbidities, including hepatic impairment, congenital long QT syndrome, and clinically significant cardiac arrhythmias.

Egyéb

• Participants unable to provide a written consent for the study.

• Participants with clinically confirmed diagnosis of chorea associated with Huntington's Disease (HD)
• Participants whose baseline total maximal chorea (TMC) score ≥ 8
• Participants who are deutetrabenazine-naïve before study entry or who did not receive deutetrabenazine within 30 days of study entry, and who are about to be treated with deutetrabenazine for chorea associated with HD
• Participants who have provided written consent for the use of personal and medical information for study purposes